Background-Portal systemic encephalo-
Portal systemic encephalopathy (PSE) is a complex neuropsychiatric syndrome associated with hepatic failure, which is characterised by central nervous system depression and an increase in portal systemic shunting.' In clinical practice the severity of PSE can be graded into four stages (I to IV) based on the mental state and neuromuscular function of the patient using criteria such as sleep disorders, disorientation, somnolence, stupor, and coma.23
Animal studies have shown that antagonists of y-aminobutyric acid and benzodiazepines can attenuate the increased neural inhibition associated with PSE.4 Flumazenil (Ro , the first competitive benzodiazepine receptor antagonist, has a high affinity for the benzodiazepine receptor, and rapidly reverses the hypnotic-sedative effects of benzodiazepines following intravenous administration.5 6 The score items were weighted so that major disturbances of consciousness (PSE stage III and IV) were associated with scores of 11 or higher. PSE stage II was defined to range from scores of 5 to 10 and stage I from 3 to 4. PSE was also categorised according to electroencephalogram (EEG) characteristics, based on a combination of visual inspection or automated EEG analysis, or both, by one central assessor (G Scollo-Lavizzari).l6 17 This evaluation was done under double blind conditions and the assessor was not aware of the clinical outcome.
Care was taken to exclude PSE episodes resulting from precipitating clinical conditions that could interfere with the effect of flumazenil on PSE. Consequently PSE episodes resulting from common precipitating situations such as severe bleeding and infection (for example, sepsis) were excluded resulting in a selection of patients with apparently more spontaneous and stable PSE in chronic liver disease.
Furthermore, patients with acute fulminant liver failure, coma (PSE/stage IV) at any point of the study, metabolic coma other than due to liver failure, hepatitis superimposed on cirrhosis, liver tumours, severe cerebral atrophy as assessed by cranial computer aided tomography, and psychiatric disease except PSE as well as patients who reported to have taken psychotropic medication (including benzodiazepines) were excluded from the study. In addition, screening tests in blood and urine samples for opiates, barbiturates, and benzodiazepines (Abbott TDX, Abbott Laboratories, Chicago, IL, fluorescence-polarisation immunoassay, with a detection limit 10-100 ngfml in blood, 6200 ng/ml in urine) were performed during the baseline period.
As the sensitivity and specificity of the screening test is limited, the biological material was frozen and afterwards analysed by a central laboratory for benzodiazepines using a sensitive high pressure liquid chromatography (HPLC) method (sensitivity: s50 ngfml in blood and 10-100 ng/ml in urine). Patients were randomised and the treatment was started before the results of the screening test were available. Patients are therefore included in the intent to treat analysis independent of the fact that they had a positive benzodiazepine test or not, but patients with a positive benzodiazepine test were excluded from the per protocol analysis.
The severity of the underlying liver disease was assessed according to the Child-Pugh grading system.18
The study was 12 hours in duration and consisted of three periods: a four hour baseline observation period, a three hour double blind treatment period, and a five hour post-treatment observation period. After the baseline observation period, patients were randomised to receive (at one minute intervals) three sequential bolus injections of flumazenil (0.4, 0.8, and 1 mg) or placebo, after which patients were given either intravenous infusions of either flumazenil (1 mg/h) or placebo for three hours. Only the following additional treatments were permitted: saline, glucose, lactulose, potassium, and vitamin K. Clinical PSE grading was performed at 60 minute intervals during the baseline and post-treatment periods and every 30 minutes during treatment. The first assessment took place within five minutes of the bolus injections. At each time point, vital signs and rectal body temperature were recorded. EEG recordings were made continuously during the first and the last 20 minutes of each period.
Response was defined as improvement in the average PSE score (mean of all individual scores) during treatment and post-treatment compared with baseline, whereas a clinically relevant improvement was defined as a two point improvement in PSE score at any time during treatment compared with baseline. Child-Pugh score (n) Clinical PSE scores and EEG grades were compared both regarding severity and improvement. Clinical experience with flumazenil has shown that its onset of action is generally very rapid.6 As these rapid changes could be blurred by focusing on average scores, a separate assessment of the changes between the time points immediately before (last baseline score) and immediately after the fractionated bolus administration of flumazenil (first treatment score) was performed.
Safety evaluations included registration of adverse events and detailed blood laboratory investigations at baseline and at the end of the post-treatment observation period.
Statistical analyses
Statistical analyses were performed on two different patient populations. All patients randomised with at least one on drug observation constitute the intent to treat population, whereas patients deviating from protocol were excluded from the evaluation of the per protocol population. Clinical response data were analysed using a rank test for independent samples (Wilcoxon two sample test with continuity correction of 0.5),18 while the numbers of patients in both treatment groups showing clinically relevant improvement were compared using Fisher's exact test.
Results
Of the 49 patients enrolled and constituting the intent to treat sample, 24 patients did not comply with the strict inclusion criteria leaving 25 patients in the per protocol sample. The most frequent reason for exclusion from the per protocol population was of technical nature. For 12 patients, the frozen plasma and urine samples were lost during transportation to Switzerland. The presence of benzodiazepines at measurable concentrations in plasma or urine could therefore not be excluded in these patients. Other reasons were positive benzodiazepine screening, liver tumour, severe cerebral atrophy, and incomplete PSE scoring (Table I) . Table II (Fig 2) . The graph clearly shows that no linear relation exists between these parameters. In patients with a mild degree of PSE (PSE z5), all degrees of EEG abnormality from minor to severe were found. However, with higher degrees of clinical impairment (PSE >5), all but two patients were categorised as EEG stage III or IV.
For technical reasons, EEG recordings were obtained in only 33 patients. In view of the low numbers, it was decided not to use EEG as a separate efficacy parameter in this report.
Adverse events considered possibly or probably related to treatment occurred in four patients in the flumazenil group, the symptoms being flushing, nausea and vomiting, nausea and irritability, of which only irritability was graded as severe. There were no adverse events in the placebo group, although one patient died from respiratory failure during the course of the study. Clinical and EEG responses were not associated with any significant changes in body temperature or vital signs and deviations in laboratory parameters from baseline occurred independently of the study medication.
As expected in such severely ill patients, a total of nine deaths occurred within four weeks following the study (four flumazenil and five placebo). However, these deaths were not considered related to study medication.
Discussion
This study is, to our knowledge, the first fully published controlled randomised trial of flumazenil in patients with PSE stage I-III and was undertaken in response to somewhat inconsistent results from studies involving flumazenil in PSE associated with chronic liver disease.2 8-13 18 Patients were only included if they had chronic liver failure associated with stable mild to moderate PSE (I-III; score 3-14) thereby excluding such complicating factors as cerebral oedema. Care was taken to exclude patients in whom PSE was precipitated by severe bleeding or infection as these patients have a favourable prognosis once the causative factors have been controlled. This population was therefore inherently different from those in previous double blind studies1' 12 in that a less favourable outcome would be expected.
A clinically relevant response was seen in 25-36% of patients receiving flumazenil, but in none of the placebo treated patients and the difference was statistically significant. The small number of patients showing any change in PSE score in this study prevented the group mean score becoming significant, though the mean improvement in PSE score was higher in the flumazenil group than in the placebo group. The rate of responders in this study is in keeping with that of the double blind trial by Pomier-Layrargues et a113 in cirrhotic patients with hepatic coma but distinctly lower than that in some uncontrolled series. [8] [9] [10] In the latter studies methodological weaknesses such as the lack of a proper experimental design and the nonexclusion of patients previously exposed to benzodiazepine drugs might account for the high success rate. In this study, intake of benzodiazepines was ruled out by taking a careful medical history from each patient and appropriate search for benzodiazepines in blood and urine.
Because of the small total number of responders, subgroups of patients with PSE that may benefit from flumazenil treatment could not be determined. However, the fact that 43% of patients with PSE III responded, compared with only 14% of patients with PSE II, suggests that a clinically relevant response is more likely among more severely ill patients. These results are in line with 1~3 those reported in patients with hepatic coma. 13 Although responses to flumazenil are normally expected to occur immediately after administration, this was the case in only five of seven responders. However, it is possible that an earlier response may have been missed in the other two patients because PSE scores were not assessed until 30 and 60 minutes after drug administration. The phenomenon of a somewhat delayed response has also been seen in an uncontrolled study by Grimm et al.9
In general, EEG grading did not correlate well with PSE score, although a distinction between minor (EEG I and II) and severe (EEG III and IV) impairment could be noted in patients at a clinical PSE score of 5/6 or less (that is, PSE I and II 20 it should be sensitive enough to exclude clinically relevant concentrations of exogenous benzodiazepine, which also represented the original rationale.
As the general exclusion of patients without the sensitive screening assessment could be questioned as being over-rigorous, the analysis of the intent to treat population received the same attention as the per protocol population. Presence of benzodiazepine did not seem to be an important problem in this study because only four of 49 patients had to be excluded from per protocol analysis in retrospect because of positive benzodiazepine results. It is noteworthy that two of three benzodiazepine positive patients in the fiumazenil group did not respond to fiumazenil, whereas the third one showed only a weak response (average improvement during treatment versus baseline 0.5 PSE points). This is in keeping with the finding of PomierLayrargues et a113 that the efficacy of flumazenil in PSE may not be related to the presence or absence of benzodiazepines in blood.
In conclusion, this study confirms previous data that have suggested that agonists at the benzodiazepine receptor may have a significant role in the pathogenesis of PSE. However, it remains to be determined whether these agonists are of endogenous origin or exogenous compounds that could not be detected by the assays used. Considering the sometimes critical clinical situation in these patients, the demonstrated response, together with the reported safety in this patient population, may justify the clinical use of flumazenil in patients with PSE.
